<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777985</url>
  </required_header>
  <id_info>
    <org_study_id>0722</org_study_id>
    <secondary_id>2007-005333-11</secondary_id>
    <nct_id>NCT00777985</nct_id>
  </id_info>
  <brief_title>Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea</brief_title>
  <acronym>BOSAS</acronym>
  <official_title>Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compared the effects of bosentan, an endothelin receptor antagonist, and nasal
      continuous positive airway pressure (nCPAP), obstructive sleep apnea current reference
      treatment, on diastolic blood pressure in untreated mildly hypertensive sleep apnea patients.

      The hypothesis is that blocking endothelin receptors with a drug will have the same systemic
      blood pressure lowering effect than nCPAP in sleep apnea patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour mean diastolic blood pressure</measure>
    <time_frame>before and after each treatment completion (4 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peripheral Arterial Tonometry measure</measure>
    <time_frame>before and after each treatment completion (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean 24 hour systemic systolic blood pressure</measure>
    <time_frame>before and after each treatment completion (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean 24 hour nocturnal blood pressure</measure>
    <time_frame>before and after each treatment completion (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carotid Intima Media Thickness</measure>
    <time_frame>before and after each treatment completion (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating inflammation markers (RANTES, MCP-1, TNF-alpha, INF-gamma, IL-6, IL-10 and TGF-gamma</measure>
    <time_frame>before and after each treatment completion (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Big ET1 and ET1 levels</measure>
    <time_frame>before and after each treatment completion (4 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>62.5 mg b.i.d for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>TRACLEER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nasal continuous positive airway pressure (CPAP)</intervention_name>
    <description>Daily application throughout sleep for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented obstructive sleep apnea

          -  with untreated mild systemic hypertension

        Exclusion Criteria:

          -  pregnancy or lactation

          -  daytime alveolar hypoventilation

          -  severe arterial hypertension (systolic pressure &gt; 180 mmHg; diastolic pressure &gt; 110
             mmHg)

          -  treatment with anti-hypertensive drugs

          -  cardiovascular disorder other than mild hypertension

          -  severe daytime sleepiness (score on the EPWORTH sleepiness scale ≥15) or at-risk
             occupation

          -  contra-indication to nCPAP treatment

          -  known allergy to bosentan

          -  active treatment with a drug whose efficacy is reduced by cytochromes P450, 2C9, 3A4
             and2C19 isoenzyme activation

          -  active treatment with a drug acting on systemic arterial blood pressure or endothelial
             function

          -  liver or kidney dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine H Launois, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular system</keyword>
  <keyword>Sleep</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Endothelin system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

